Clinical Trial: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/The safety of KRN23 assessed by number and types of adverse events, laboratory tests
Original Primary Outcome: Same as current
Current Secondary Outcome: Profiles of pharmacokinetics [ Time Frame: Pre-dose, 24, 48, 96, 168, 336, 504, 672, 840, 1176 hours post-dose ]
Original Secondary Outcome: Same as current
Information By: Kyowa Hakko Kirin Co., Ltd
Dates:
Date Received: July 2, 2014
Date Started: July 2014
Date Completion:
Last Updated: February 28, 2017
Last Verified: February 2017
